1 / 83

Staying on Track: The Importance of Timely Adolescent Immunizations

Staying on Track: The Importance of Timely Adolescent Immunizations. Colleen Kraft, M.D., FAAP. Caring for Adolescents. Physical/Developmental Prevention and Anticipatory Guidance Immunizations and Adolescents Barriers to Adolescent Immunizations

kirsi
Download Presentation

Staying on Track: The Importance of Timely Adolescent Immunizations

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Staying on Track: The Importance of Timely Adolescent Immunizations Colleen Kraft, M.D., FAAP

  2. Caring for Adolescents • Physical/Developmental • Prevention and Anticipatory Guidance • Immunizations and Adolescents • Barriers to Adolescent Immunizations • Meningococcal, Tdap, HPV, Varicella, Hepatitis A and B • Strategies to Improve Immunizations Rates in Adolescents

  3. Physical Changes • Extremities grow faster than trunk and head • Facial proportions change, nose and chin enlarge first • Figure changes: • Pelvis enlarges in females • Shoulders enlarge in males • Subcutaneous fat increases • Increased function of sweat glands • Increased function of sebaceous glands

  4. Secondary Sexual Characteristics: Girls • Breast enlargement begins 8-13years • Axillary hair develops 11 to 14 years • Pubic hair develops 9-12 years • Menarche begins 10-16 years Boys • Genital enlargement begins 9-13 years • Axillary hair begins 12-14 years • Facial hair develops 11-14 years • Pubic hair develops 12-15 years

  5. Functional Development • An increase in self-awareness, self-consciousness, and self-appraisal • Becoming pre-occupied with how they measure up to their peers • Continue to need family to provide acceptance and feeling of self-worth

  6. Intellectual Development • The excitement of thinking through possibilities leads to argumentativeness • The joy of putting across ideas and listening to ideas of peers leads to constant gabfests and hours on the phone • Concrete to abstract capabilities can be late and affect school performance

  7. Adolescent Autonomy • Limit testing (challenging rules) • Experimental Behavior (smoking, alcohol) • Risk taking (driving, drugs, sexuality) • Need for control (resisting authority) • Being listened to is more important than getting one’s way

  8. Adolescent Health Problems • Mortality • Accidents • Homicide • Suicide • Sexually Transmitted Infections • Substance use/abuse • Life long health habits • Eating/Exercise • Smoking

  9. Adolescent Problem BehaviorsMultifactorial • Community - Media, economic, availability of drugs and firearms. • Family-conflict, domestic violence, and substance abuse • School and Peers- academic status, friends’ behaviors, and early antisocial behavior.

  10. Protective factors • Effective parenting • Positive adult connection • Positive self esteem • Spirituality • Optimistic outlook • Safe community • Socioeconomic advantages

  11. Prevention Strategies • Promote competence and self-regulation • Education especially for adolescents in high-risk environments • Mentoring and opportunities to serve • Anticipatory guidance • Immunizations

  12. Adolescent Immunization Schedule

  13. New- 2008 Adolescent Immunization Schedule • HPV:0, 2, 6 mos. routine at 11-12 yrs. of age Eligible: 9-26 yrs. • Influenza:universal • Tdap:Single dose to replace Td booster, wound care • Meningococcal:1 dose MCV4 for 11-12 year olds, high school entry, college freshmen • Hep A:high risk, all who wish • Hep B:complete series for all • Varicella:catch-up 2nd dose

  14. The Rationale for Emphasizing Adolescent Immunization • Adolescent immunization protects during a period of increased risk • Adolescent immunization can prevent lifelong complications • Adolescent immunization can increase herd immunity

  15. Adolescent immunization rates fall short of pediatric rates “We need to utilize all possible resources to immunize and protect adolescents against vaccine-preventable diseases.” 3 • *MMR, hepatitis B, varicella immunization • NCQA. The State of Health Care Quality, 2005. • 2. CDC. MMWR. 2005;54:717-721. • 3. Society for Adolescent Medicine. J Adolesc Health. 2006;38:321-327.

  16. Well Visits By Age

  17. Barriers to immunizing adolescents • Fewer well visits during the teenage years1 • Scheduling difficulties posed by school, sports, and extracurricular activities • Lack of transportation • Insurance issues • Missed opportunities to immunize1 • Providers simply forget to vaccinate during well visits, including preparticipation sports physicals • Providers misunderstand vaccine contraindications1,2 • Lack of population-based immunization registries that include adolescents • Oster NV et al. J Am Board Fam Pract. 2005;18:13-19. • VHC. Immunization Tool Kit. April 2005.

  18. Barriers to immunizing adolescents (cont’d) • Lack of motivation by families • Adolescents and parents underestimate the risks posed by vaccine-preventable diseases1 • Many states do not require adolescent immunizations for school • Misperceptions about vaccine safety • Patient resistance to vaccines (eg, needle phobia) • Oster NV et al. J Am Board Fam Pract. 2005;18:13-19.

  19. Identifying Solutions • Recommendations of Society for Adolescent Medicine • Development of 3 distinct adolescent vaccination visits/platforms • Use of existing systems • Simultaneous administration of multiple vaccines Source: Journal of Adolescent Health 2006

  20. Identifying Solutions • Recommendations of Society for Adolescent Medicine • Use of “non-comprehensive” visits • Use of alternative vaccination sites • Education of providers and parents/adolescents Source: Journal of Adolescent Health 2006

  21. Adolescent Vaccination Platforms • 11-12 year platform • Primary platform endorsed by ACIP • Coincides with need for sports physicals • Coincides with discussions on puberty and sexuality

  22. Adolescent Vaccination Platforms • 14-15 year platform • Catch up on missed vaccinations • Complete multiple dose vaccination regimens • Coincides with need for sports physicals

  23. Adolescent Vaccination Platforms • 17-18 year platform • Catch up on missed vaccinations • Complete multiple dose vaccination regimens • Complete regimens while still covered by VFC or third party payors

  24. Use of Non-comprehensive Visits • Minor illness/injury visits • Potentially controversial • Parent education on true and false contraindications to immunizations • Camp/Sports physicals • Pre-college visits

  25. Meningococcal Disease N Engl J Med. 2001;344:1372

  26. Meningococcal Disease: Still a Major Health Concern • Meningococcal disease continues to cause significant morbidity and mortality in the US • Rates of meningococcal disease beyond infancy begin to rise in early adolescence, peaking at 17 years of age • Older adolescents have a 5-fold greater fatality rate than those <15 years old • Conjugate vaccines induce immunologic memory and herd immunity • The attributes of conjugate vaccines give them more widespread utility than polysaccharide vaccines 1. Harrison LH, et al. JAMA. 2001;286:694. 2. Granoff DM, et al. In: Vaccines. 4th ed. 2004: 959.

  27. ACIP Recommendations for Use of Meningococcal Vaccine • Routine vaccination of adolescents with MCV-4 • Young adolescents 11 to 12 years (during the pre-adolescent visit), OR • Teens entering high school (15 years), OR • Incoming college freshmen (18 years) living in dormitories CDC. MMWR. 2005;54(RR-7):13.

  28. ACIP Recommendations • Routine vaccination of other populations at increased risk • Microbiologists who are routinely exposed to isolates of Neisseria meningitidis • Military recruits • Persons who travel to, or reside in, countries in which N meningitidis is hyperendemic or epidemic • Complement-deficient and asplenic patients

  29. Practice Recommendation • Tdap and tetravalent meningococcal conjugate vaccine (which both contain diphtheria toxoid) should be administered to adolescents aged 11-18 years during the same visit if both vaccines are indicated and available • Approved Source: National Guideline Clearinghouse • Website: http://www.guideline.gov/summary/summary.aspx?doc_id= 8818&nbr=004864&string=acip+and+pertussis • Strength of Evidence: 1-A:1 Efficacy against and tetanus, diphtheria, and pertussis is supported by immunogenicity results of randomized, controlled clinical trials among adolescents; safety is supported by results of randomized, controlled clinical trials among adolescents.

  30. Meningococcal Revaccination • Revaccination may be indicated for persons at high risk for infection* who received Menomune at least 5 years ago • Once a person has received MCV no further meningococcal vaccination is recommended (at this time)

  31. Responses to Initial Reports of GBS Following Receipt of Menactra Vaccine • Initial report September 30, 2005 - 5 confirmed cases of GBS reported to the Vaccine Adverse Event Reporting System (VAERS) • New Vaccine Information Sheet (VIS) published on October 7th • Package Insert Revised – November 2005 • Previous GBS listed as contraindication • Temporal relationship between GBS and MCV4 in Warning section • Further monitoring and studies ongoing

  32. Updated Information on Reports of GBS Following Receipt of Menactra Vaccine • In April 7, 2006 MMWR*, Centers for Disease Control and Prevention (CDC) states that: • Only 3 cases reported since October 2005, suggesting that MCV4 [Menactra vaccine] might not be causally related to GBS; • Available evidence neither proves nor disproves causal relation between GBS and Menactra vaccine; • Reported incidence remains similar to the expected incidence • Rate of GBS following Menactra vaccine is similar to what would be expected by chance alone • Background incidence rate of GBS is 1–2 cases/100,000 population • Ratio of reporting rate of GBS following Menactra vaccination to the expected incidence rate is 1.4 (95% CI, 0.7–2.8)* * MMWR Vol.55/No.13, pp 364-366

  33. Pertussis

  34. Reports of PertussisUnited States, 1980–2004 25,827 24 20 16 12 Cases (Thousands) 11,647 9771 7796 6586 8 4570 4 0 1980 1982 1984 1986 1988 1990 1992 1994 1996 1998 2000 2002 2004 Year CDC. MMWR. 1997;46(54):71-80. MMWR. 2000;50(51 & 52):1175. MMWR. 2001;50(33):725. MMWR. 2002;51(32):723. MMWR. 2003;52(31):747. MMWR. 2003;52(54):28, 72. Bacterial Vaccine Preventable Disease Branch, National Immunization Program, 2004; MMWR. 2005;54(31):770.

  35. Complications of Adolescent-Adult Pertussis • Complications common in adolescents (16%) and adults (28%) • Pneumonia occurs in 2% of patients <30 years old and 5% to 9% of older patients • Hospitalization of adolescents and adults at 1.4% and 3.5%, respectively • <50 y/o, 2% hospitalized, mean stay of 3 days • ≥50 y/o, 6% hospitalized, mean stay of 17 days De Serres G et al. J Infect Dis. 2000;182:174-179.

  36. Age of Pertussis Source* for Infants 60 50 40 % of Infant Cases 30 20 10 0 0-4 5-9 10-19 20+ Age of Source (Years) *219 known or suspected source-persons with known age Bisgard KM et al. Pediatr Infect Dis J. 2004;23:985-989

  37. Pertussis – adolescents and adults • More than half of cases are adolescents or adults • Family member is usual source (75%) for infant pertussis Source persons by age for infant pertussis: Adolescents and adults were source for 76% of cases Bisgard KM et al. Infant pertussis: who was the source? Ped Inf Dis J 2004;23(11):985-9.

  38. Tdap Vaccines • Boostrix • Approved for persons 10-18 years of age • Adacel • Approved for persons 11-64 years of age

  39. Tdap Vaccines • No brand preference (except as dictated by age group being vaccinated; off-label use NOT recommended) • Licensed only for a single dose • Tdap not approved or recommended for children 7-9 years of age or adults 65 years or older (use Td)

  40. DTaP and Tdap Errors

  41. Tdap - Precautions • History of Arthus-type reaction following tetanus- or diphtheria- containing vaccine • Unstable neurological conditions • Severe latex allergy • History of Guillain Barre Syndrome after tetanus-containing vaccine • Moderate or severe acute illness MMWR December 15, 2006 / 55(RR17)

  42. Contraindications • Anaphylaxis after prior dose • Unexplained encephalopathy within 7 days of pertussis-containing vaccine. Give Td. • MMWR Feb 3,2006;55(Early release):1-34

  43. NOT Precautions to Tdap • Stable neurological disorder • Pregnancy or breastfeeding • Immunosuppression • Infection, minor illness, antibiotics • History following DTaP, DTP, or DT of: • Temp 105° F or higher • Collapse or shock-like state • Crying lasting 3+ hours • Convulsions with/without fever • History of extensive limb swelling MMWR Feb 3,2006;55(Early release):1-34

  44. Practice Recommendation • ACIP Recommendations – Adolescent Pertussis Immunization • All adolescents at the 11-12 year old visit • All adolescents 11-18 not recently immunized with Td • Adolescents 11-18 who received Td and it has been a least 5 yrs • Can give Tdap and MCV4 simultaneously • Approved Source: National Guideline Clearinghouse • Website: http://www.guideline.gov/summary/summary.aspx?doc_id= 8818&nbr=004864&string=acip+and+pertussis • Strength of Evidence: see next slide

  45. Human Papilloma Virus (HPV)

More Related